DE69316013D1 - Verwendung von phosphinate zur behandlung der osteoporose - Google Patents

Verwendung von phosphinate zur behandlung der osteoporose

Info

Publication number
DE69316013D1
DE69316013D1 DE69316013T DE69316013T DE69316013D1 DE 69316013 D1 DE69316013 D1 DE 69316013D1 DE 69316013 T DE69316013 T DE 69316013T DE 69316013 T DE69316013 T DE 69316013T DE 69316013 D1 DE69316013 D1 DE 69316013D1
Authority
DE
Germany
Prior art keywords
high potency
day
thirty
potency phosphonate
phosphonate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69316013T
Other languages
English (en)
Other versions
DE69316013T2 (de
Inventor
Marion Francis
Rogely Boyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Procter and Gamble Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25422708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69316013(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Pharmaceuticals Inc filed Critical Procter and Gamble Pharmaceuticals Inc
Publication of DE69316013D1 publication Critical patent/DE69316013D1/de
Application granted granted Critical
Publication of DE69316013T2 publication Critical patent/DE69316013T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69316013T 1992-06-30 1993-06-04 Verwendung von phosphinate zur behandlung der osteoporose Revoked DE69316013T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90660992A 1992-06-30 1992-06-30
PCT/US1993/005267 WO1994000129A1 (en) 1992-06-30 1993-06-04 Use of phosphonates for the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
DE69316013D1 true DE69316013D1 (de) 1998-02-05
DE69316013T2 DE69316013T2 (de) 1998-07-09

Family

ID=25422708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69316013T Revoked DE69316013T2 (de) 1992-06-30 1993-06-04 Verwendung von phosphinate zur behandlung der osteoporose

Country Status (13)

Country Link
EP (1) EP0648120B1 (de)
JP (2) JP4481368B2 (de)
KR (1) KR950702120A (de)
AT (1) ATE161423T1 (de)
AU (1) AU659329B2 (de)
CA (1) CA2138367C (de)
DE (1) DE69316013T2 (de)
DK (1) DK0648120T3 (de)
ES (1) ES2111163T3 (de)
GR (1) GR3025792T3 (de)
HU (1) HUT70210A (de)
MA (1) MA22915A1 (de)
WO (1) WO1994000129A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
AU701258B2 (en) * 1994-12-28 1999-01-21 Gador S.A. Bone mass anabolic composition comprising olpadronate
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
ID24096A (id) * 1997-07-22 2000-07-06 Merck & Co Inc Metode untuk menghambat resorpsi tulang
AU2007211965B2 (en) * 1997-07-22 2008-05-15 Merck Sharp & Dohme Corp. Alendronate for use in the treatment of osteoporosis
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
AU2005227418B2 (en) * 1997-07-22 2008-05-29 Merck Sharp & Dohme Corp. Method for inhibiting bone resorption
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
EP1296689B3 (de) 2000-06-20 2013-02-13 Novartis AG Methode zur verabreichung von biphosphonaten
MXPA04009586A (es) 2002-05-10 2005-01-11 Hoffmann La Roche Acidos bisfosfonicos para el tratamiento y prevencion de la osteoporosis.
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
ITPA20070034A1 (it) * 2007-10-30 2009-04-30 Tetrapharm S R L Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico.
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
TWI730039B (zh) * 2016-01-29 2021-06-11 日商富士藥品股份有限公司 新穎雙膦酸化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
DE4011777A1 (de) * 1989-04-14 1990-10-18 Ciba Geigy Ag N-trisubstituierte aminoalkandiphosphonsaeuren

Also Published As

Publication number Publication date
ATE161423T1 (de) 1998-01-15
CA2138367C (en) 1998-09-22
ES2111163T3 (es) 1998-03-01
DE69316013T2 (de) 1998-07-09
AU4403893A (en) 1994-01-24
DK0648120T3 (da) 1998-01-19
EP0648120B1 (de) 1997-12-29
KR950702120A (ko) 1995-06-19
WO1994000129A1 (en) 1994-01-06
AU659329B2 (en) 1995-05-11
JP2010106042A (ja) 2010-05-13
EP0648120A1 (de) 1995-04-19
JPH07508278A (ja) 1995-09-14
CA2138367A1 (en) 1994-01-06
HUT70210A (en) 1995-09-28
GR3025792T3 (en) 1998-03-31
MA22915A1 (fr) 1993-12-31
JP4481368B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DK0573604T3 (da) Fremgangsmåde til behandling af osteoporosis
BG100517A (en) Combination of bisphosphonates and growth hormone secretagogues
KR950702121A (ko) 포스포네이트 및 비스테로이드계 소염 약물(nasid)을 함유하는 관절염 치료 조성물(compositions for the treatment of arthritis containing phosphonates and nsaids)
DE3650403T3 (de) Polyphosphonat enthaltende Packung zur Behandlung von Osteoporose.
NO942241L (de)
DE3752112D1 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
GR3022321T3 (en) Use of il-4 to treat solid tumors
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
MY104521A (en) Treatment of depression.
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
NO945058L (no) Anvendelse av fosfonater for behandling av osteoporose
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ATE72979T1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation